Fulvestrant in Treating Patients With Advanced Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells. PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with advanced prostate cancer.

Key facts

Study ID

NCT00244998

Run by

Roswell Park Cancer Institute

People needed

20

Starts

2005-09-01

Expected to finish

2012-06-01

Last updated by the study team

2013-03-08

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Roswell Park Cancer Institute — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.